❌

Reading view

OASES: Outcome-Aligned Search-Evaluation Co-Training for Agentic Search

arXiv:2604.03675v3 Announce Type: replace Abstract: Agentic search enables language models to solve knowledge-intensive tasks by adaptively acquiring external evidence over multiple steps. Reinforcement learning with verifiable rewards (RLVR) has emerged as a widely adopted training paradigm for search agents, yet outcome-only rewards are sparse and provide limited credit assignment for intermediate search actions. Existing process-reward methods therefore seek to densify supervision through proxy signals, external evaluators, or likelihood-based information gain. However, proxy rewards can deviate from the final outcome objective, while fixed evaluators can become stale as the search policy evolves, leading to unreliable process supervision. To address these challenges, we propose OASES, an Outcome-Aligned Search-Evaluation Supervision framework for agentic search. OASES derives outcome-aligned process rewards by evaluating how well each intermediate search state supports answering the original question. It further co-trains the search policy and the state evaluator on policy, allowing the evaluator to adapt to evolving search behavior and provide more reliable process rewards. Experiments on five multi-hop QA benchmarks show that OASES consistently outperforms strong RL baselines, with further analyses confirming the benefits of outcome-aligned process rewards and search-evaluation co-training.
  •  

Precision Thyroid Oncology: A Review of Multi-Omics Biomarkers and Spatiotemporal Technologies

Int J Gen Med. 2026 May 18;19:602509. doi: 10.2147/IJGM.S602509. eCollection 2026.

ABSTRACT

Thyroid cancer (TC), the most prevalent endocrine malignancy worldwide, encompasses a broad spectrum of biological behaviors ranging from indolent microcarcinomas to lethal anaplastic variants. Despite advancements in standard care, critical clinical "bottlenecks" persist, including the diagnostic ambiguity of Bethesda III/IV nodules, the rising prevalence of radioiodine-refractory (RAI-R) differentiated TC, and the dismal survival rates of anaplastic thyroid carcinoma (ATC). The rapid evolution of biomarkers has catalyzed a paradigm shift from traditional anatomical-pathological staging to a sophisticated "Molecular Taxonomy" model, providing the cornerstone for precision oncology. This review systematically delineates the multi-dimensional landscape of TC biomarkers, encompassing genomic and transcriptomic drivers (eg, BRAF, RAS, TERT, RET, NTRK), epigenetic regulators (miRNAs, lncRNAs, circRNAs, and DNA methylation), and the proteomic interface. We highlight the transformative role of Liquid Biopsy 2.0-including ctDNA-based minimal residual disease (MRD) detection and exosomal multi-omics-in enabling non-invasive, longitudinal surveillance. Furthermore, we explore how cutting-edge technologies, such as single-cell sequencing and spatial transcriptomics, are deciphering intratumoral heterogeneity and redefining the "functional invasive front". Clinical translation is addressed through the lens of personalized management: from the use of genomic classifiers (eg, ThyroSeq v3) in preoperative triage to biomarker-guided "de-escalation" or "intensification" of therapy. Finally, we discuss the imperative of addressing ancestry-specific molecular divergence (specifically in Asian cohorts). However, significant challenges remain, including the high cost of multi-omics integration and the lack of standardized protocols for clinical implementation. We conclude by envisioning a future integrated with multimodal AI models, patient-derived organoids (PDOs), and metabolic reprogramming markers, aiming to provide a holistic framework for the "early screening-precise diagnosis-tailored therapy-dynamic monitoring" continuum in thyroid oncology.

PMID:42179850 | PMC:PMC13196814 | DOI:10.2147/IJGM.S602509

  •  
❌